Contribution of extracellular particles isolated from Morus sp. (mulberry) fruit to their reported protective health benefits: an in vitro study

Abstract

Morus sp. (mulberry), have a long tradition of use as medicinal treatments, including for cardiovascular disease and type 2 diabetes, being shown to have antioxidant properties and to promote wound healing. Extracellular vesicles (EVs) are sub-micron, membrane-enclosed particles that were first identified in mammalian bodily fluids. EV-like particles have been described in plants (PDVs) and shown to have similar characteristics to mammalian EVs. We hypothesised that some of the health benefits previously attributed to the fruit of Morus sp., could be due to the release of PDVs. We isolated PDVs from Morus nigra and Morus alba by ultracentrifugation, and incubated THP-1 monocytes, differentiated THP-1 macrophages, or HMEC-1 endothelial cells with pro-oxidant compounds DMNQ (THP-1) and glucose oxidase (HMEC-1) or lipopolysaccharide (LPS), in the presence of different fractions of mulberry EVs. Mulberry EVs augmented ROS production by DMNQ in THP-1 and caused downregulation of ROS in HMEC-1. Mulberry EVs increased LPS-
induced IL-1b secretion, but reduced CCL2 and TGF-b secretion in THP-1 macrophages. In scratch wound assays, mulberry EVs inhibited HMEC-1 migration but increased proliferation in both low and high serum conditions, suggesting that they have opposing effects in these two important aspects of wound healing. One of the limitations of plant-derived therapeutics has been overcoming low bioavailability of isolated compounds. We propose that PDVs could provide the link between physiological dose and therapeutic benefit by protecting plant active compounds in the GIT as well as potentially delivering genetic material or proteins that contribute to previously observed health benefits.